FDA Approves Ajovy for the Preventive Treatment of Migraines

FDA Approves Ajovy for the Preventive Treatment of Migraines

The FDA has approved Ajovy (fremanezumab-vfrm) injections for the preventive treatment of migraines. Ajovy will be available in 225 mg monthly doses, or 675 mg quarterly doses.

Ajovy is a calcitonin gene-related peptide (CGRP) antagonist. GRPS are found in high levels in the blood during migraines and blocking CGRPs has been found to reduce migraine frequency. One of Ajovy’s Phase 3 clinical trials involved 1,130 patients, reducing the average number of monthly migraine days during a 12-week period by at least four days, varying depending on dose schedule.

Ajovy is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Common adverse reactions include injection site reactions.